AntonioMarcilio PadulaOmuroMD

Clinical Trials

• Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Start of enrollment: 2007 Jun 01

  Completed

  Phase 2

• Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine Start of enrollment: 2007 Jul 01

  Unknown status

  Phase 2

• Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma Start of enrollment: 2002 Sep 01

  Completed

  Phase 2

• Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Start of enrollment: 2002 Aug 28

  Completed

  Not Applicable

• Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma Start of enrollment: 2004 Dec 01

  Completed

  Phase 2

• A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Start of enrollment: 2008 Aug 01

  Unknown status

  Phase 1, Phase 2

• Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma Start of enrollment: 2008 Oct 28

  Completed

  Phase 2

• Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas Start of enrollment: 2010 May 01

  Active, not recruiting

  Phase 1

• RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Start of enrollment: 2010 May 01

  Completed

  Phase 1

• Carboplatin and Bevacizumab for Recurrent Ependymoma Start of enrollment: 2011 Apr 27

  Completed

  Phase 2

• Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma Start of enrollment: 2011 Jul 08

  Completed

  Phase 1

• Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Start of enrollment: 2011 Sep 01

  Completed

  Phase 2

• Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2012 Nov 01

  Completed

  Phase 1, Phase 2

• A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients Start of enrollment: 2014 Feb 07

  Active, not recruiting

  Phase 3

• Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype Start of enrollment: 2016 Jan 22

  Active, not recruiting

  Not Applicable

• Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Start of enrollment: 2018 Oct 30

  Terminated

  Phase 1

• Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29

  Recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• Join now to see all